Compare Merck & Co., Inc. (MRK) vs WD 40 Company (WDFC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Merck & Co., Inc. vs WD 40 Company — how do they compare? Merck & Co., Inc. trades at $132.3 (market cap $321.77B), while WD 40 Company trades at $232.11 (market cap $3.13B). The key difference: Merck & Co., Inc. is far larger — about 102.8× WD 40 Company's market cap, and Merck & Co., Inc. pays the higher dividend (2.61%). Which is the better fit depends on your goals.
| MRK | WDFC | |
|---|---|---|
Market Cap | $321.77B | $3.13B |
Sector | Health | Technology |
52-Week High | $131.84 | $264.91 |
52-Week Low | $77.60 | $187.52 |
Enterprise Value | $368.53B | $3.18B |
Dividend Yield | 2.61% | 1.75% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Merck (MRK) trades at $130.9, up 1.81% today, with a bullish technical outlook supported by moving averages and a consensus analyst price target of $140.36. Recent earnings beats and a 72.97% gross margin highlight strong profitability, while the acquisition of Terns Pharmaceuticals aims to bolster its oncology pipeline. The stock faces headwinds from a high P/E ratio of 104.34 and fluctuating cash flows.
The outlook is positive with robust fundamentals and strategic M&A, but valuation concerns and competitive pressures in pharma pose risks. Upside is likely if earnings growth continues, though investors should monitor debt levels and integration of acquisitions.
WD-40 Company (WDFC) trades at $232.9, down 0.69% today, with strong technical momentum showing bullish moving averages and key support at $230. The company reported impressive Q2 2026 earnings of $2.33 per share, beating estimates by 49%, while revenue growth continues with 2026 projections at $675 million. Recent news highlights institutional buying and positive analyst coverage, though valuation metrics remain elevated with a P/E of 35.39.
WDFC demonstrates solid fundamentals with consistent profitability (13.22% net margin) and strong brand positioning, but faces margin pressure from rising input costs. Analyst sentiment is mixed with 71% hold ratings, suggesting cautious optimism. Key risks include valuation concerns and cost inflation, while the company's dividend policy and global brand recognition provide stability for long-term investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →About WD 40 Company
WD-40 Company is a global marketing organization dedicated to creating 'positive lasting memories' by developing and selling products that solve maintenance and cleaning problems. Built around the legendary WD-40 Multi-Use Product, the company operates an asset-light business model, focusing on brand management and innovation while utilizing a network of contract manufacturers to deliver solutions across the Americas, EIMEA, and Asia-Pacific.
Read more on WDFC →
